Make up a missed lesson-New policy to ensure the interchangeability of generic drugs in China

被引:18
作者
Huang, Baobin [1 ,2 ]
Barber, Sarah L. [1 ,2 ,3 ]
Xu, Mingzhe [1 ,2 ]
Cheng, Shuanghong [1 ,2 ]
机构
[1] Natl Inst Food & Drug Control, Div Gen Management, 2 Tiantanxili, Beijing 100050, Peoples R China
[2] WHO Collaborating Ctr Drug Qual Assurance, Beijing, Peoples R China
[3] WHO Representat Off S Afr, Pretoria, South Africa
来源
PHARMACOLOGY RESEARCH & PERSPECTIVES | 2017年 / 5卷 / 03期
关键词
Bioequivalence studies; clinical trial; comparators; drug regulation; efficacy; essential medicines; generic drugs; generic drugs industry; interchangeability; quality; re-evaluation; MEDICINES; COULD;
D O I
10.1002/prp2.318
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Generic drugs should be interchangeable with originators in terms of quality and efficacy. With relative lower prices, generic drugs are playing an important role in controlling health expenditures and ensuring access. However, the widespread understanding of "cheap price equals low quality" has a negative impact on the acceptance of generic drugs. In China, medical doctors doubt the efficacy and quality of generic drugs manufactured domestically. To address these concerns, the Chinese State Council released a policy in 2016 to ensure the interchangeability by re-evaluating the quality and efficacy of generic drugs. It intends to make up a missed lesson in the regulation to be in line with internationally accepted practices. Generic drugs firms, depends on the availability of appropriate comparators, should conduct either comparative bioequivalence studies or full scale clinical trials. The re-evaluation will be implemented in a stepwise approach with the essential medicines covered in the first step. The policy could achieve several benefits by increasing confidence on the Chinese produced generic drugs, upgrading regulatory standards, streamlining the Chinese generic drug industry and creating a healthy competition market. Nevertheless, enormous challenges remain in enlarging the capacity to review applications, selecting appropriate comparators, ensuring the capacity of domestic clinical research sites, and achieving the acceptance of re-evaluated generic drugs.
引用
收藏
页数:3
相关论文
共 6 条
[1]   The need to incorporate generic medicines topic in the curriculum of Yemeni pharmacy colleges [J].
AL-Tamimi, Saleh Karamah ;
Hassali, Mohamed Azmi ;
Shafie, Asrul Akmal ;
ALrasheedy, Alian A. .
INTERNATIONAL JOURNAL OF PHARMACY PRACTICE, 2016, 24 (01) :72-73
[2]   The Need to Cover Generic Medications and Generic Substitution Practice in the Curricula of Pharmacy Colleges in Saudi Arabia [J].
Alrasheedy, Alian A. ;
Hassali, Mohamed Azmi ;
Aljadhey, Hisham ;
Al-Tamimi, Saleh Karamah .
AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION, 2014, 78 (05)
[3]   Switching from Originator Brand Medicines to Generic Equivalents in Selected Developing Countries: How Much Could Be Saved? [J].
Cameron, Alexandra ;
Mantel-Teeuwisse, Aukje K. ;
Leufkens, Hubert G. M. ;
Laing, Richard Ogilvie .
VALUE IN HEALTH, 2012, 15 (05) :664-673
[4]  
Nguyen Tuan A, 2013, WHO South East Asia J Public Health, V2, P72, DOI 10.4103/2224-3151.115849
[5]   How much could be saved in Chinese hospitals in procurement of anti-hypertensives and anti-diabetics? [J].
Sun, Jing ;
Ren, Luo ;
Wirtz, Veronika .
JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (09) :881-888
[6]  
U. S. Food and Drug Administration (FDA), 2015, WHAT AR GEN DRUGS